Company / Capital Expenditures
Amylyx Pharmaceuticals, Inc. Capital Expenditures History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$138.0K
FY2025
5-year range
$138.0K / $2.5M
FY2021-FY2025
Trend
-12.1%
vs FY2024
Sector context
#166 of 194
Health Care
What the data says
Amylyx Pharmaceuticals, Inc.'s capital expenditures of $138,000 is lower than 86% of companies in the Health Care sector (FY2025). Capital Expenditures has declined for 3 consecutive years, from $3M in FY2022 to $138,000 in FY2025.
Based on SEC 10-K filings.
$138,000 in FY2025 with a 3-year CAGR of -62.1%.
Declined from $1M to $138,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -62.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 194This company $138.0K Sector average $117.5M
▼
-99.9% below sector average
Key checks
Key Insights
- Amylyx Pharmaceuticals, Inc.'s capital expenditures has declined for 3 consecutive years.
- 3-year CAGR of -62.1%, indicating a declining trend.
- In FY2025, capital expenditures decreased 12.1% year-over-year.
- Ranks #166 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $138.0K | -12.1% |
| FY2024 | $157.0K | -87.3% |
| FY2023 | $1.2M | -50.9% |
| FY2022 | $2.5M | +615.6% |
| FY2021 | $353.0K | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026